Search

Displaying results 2231 - 2240 of 10000 in total
  1. Drug

    Serdexmethylphenidate

    go.drugbank.com/drugs/DB16629
    Approved

    [L32298, L32323] Serdexmethylphenidate was granted FDA approval on March 2, 2021, and is currently marketed as a combination capsule with [dexmethylphenidate] under the trademark AZSTARYS™ by KemPharm … [A230698, A230708] Serdexmethylphenidate is a prodrug of the CNS stimulant [dexmethylphenidate], a common first-line treatment for ADHD, that is combined with [dexmethylphenidate] to provide extended plasma

  2. Drug

    Levosalbutamol

    go.drugbank.com/drugs/DB13139
    Approved

    [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. … Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).

  3. Drug

    Lotilaner

    go.drugbank.com/drugs/DB17992
    ApprovedInvestigationalVet approved

    Lotilaner is an ectoparasiticide that is a member of the isoxazoline family of compounds. … [L47546] Lotilaner has largely been used for veterinary uses as an antiparasitic agent to treat flea and tick infestations in animals.

    Synonyms: 2-thiophenecarboxamide, 5-((5s)-4,5-dihydro-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-3-isoxazolyl)-3-methyl-n-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-, 3-methyi-n-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-5-((55)-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl)thiophene-2-carboxamide
  4. Drug

    Lecithin, soybean

    go.drugbank.com/drugs/DB14161
    Investigational

    The emulsifying and surfactant properties are useful in food additives and for forming organogels (gels). … Lecithin is a component of the cell membrane and commercially extracted from soybeans and egg yolk.

    Mixtures: GNC PP AA FormulaProducts: Essentiale Forte N
  5. Drug

    DL-dimyristoylphosphatidylglycerol

    go.drugbank.com/drugs/DB11284
    Approved

    DL-dimyristoylphosphatidylglycerol is a phospholipid used in commercially available pharmaceutical preparations to solubilize drugs for injection.

  6. Drug

    Amiloxate

    go.drugbank.com/drugs/DB11207
    Approved

    Amiloxate is a cinnamic acid derivative with an anti-inflammatory activity [A32916]. … Amiloxate is an EMA-approved chemical UV-filter found in over-the-counter sunscreen products at concentrations up to 10%m [F35].

    Mixtures: Super Plus Beblesh Balm Triple Functions SPF50 Plus PA 3Plus (40g)
  7. Drug

    Encorafenib

    go.drugbank.com/drugs/DB11718
    ApprovedInvestigational

    melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. … Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations.

  8. Drug

    Decitabine

    go.drugbank.com/drugs/DB01262
    ApprovedInvestigational

    [L14962] It is also available as an oral combination product together with the cytidine deaminase inhibitor [cedazuridine]. … Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis.

  9. Drug

    Taurolidine

    go.drugbank.com/drugs/DB12473
    ApprovedInvestigational

    It was first synthesized in the 1970s and was originally used as a prophylactic against intraperitoneal bacterial infections in patients with peritonitis. … Taurolidine is an antimicrobial used for the prevention of catheter-related infections. It is a derivative of the amino acid [taurine].

  10. Drug

    Acenocoumarol

    go.drugbank.com/drugs/DB01418
    ApprovedInvestigational

    Acenocoumarol is a coumarin derivative used as an anticoagulant. Coumarin derivatives inhibit the reduction of vitamin K by vitamin K reductase. … Patients on acenocoumarol are prohibited from giving blood.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index